US · Healthcare · Biotechnology
Analysts rate Korsana Biosciences, Inc. a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $44.00.
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Revenue was $0; the company reported a net loss of $77.295 million for the nine months ended September 30, 2026, compared with $21 | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Cash and cash equivalents were approximately $456.2 million as of September 30, 2026, compared with $154.1 million at December 31, | 2026-11-05 |
| Proxy statement · Q4 2026 EXECUTIVE PAY • CEO total compensation and change: The provided proxy-statement excerpt does not disclose Jonathan Violin, Ph.D.’s total compensation | 2026-10-15 |
| Results announced · Q3 2026 KORSANA BIOSCIENCES, INC. – FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position (June 30, 2026): $121.2 million in cash and cash equivalents; $101,00 | 2026-09-11 |
| Shareholder vote results · Q3 2026 CYCLERION THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Shareholder meeting held: August 26, 2026 • Shares outstanding (record date July | 2026-08-27 |
| Company announcement · Q3 2026 CYCLERION THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) • Document date: August 25, 2026 | 2026-08-25 |
| Quarterly report · Q2 2026 CYCLERION THERAPEUTICS, INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $1,391k at June 30, 2026 vs. $3,240k at December 31, 2025 (5 | 2026-08-04 |
| Quarterly report · Q1 2026 CYCLERION THERAPEUTICS, INC. — 10-Q SUMMARY Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Cash position: $2.823 million (down from $3.240 mil | 2026-05-12 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 1 : 7 effective Sep 9, 2026 | 2026-09-09 |
| Announcement | Date |
|---|---|
| Completed merger with another biotech alongside a concurrent private placement Korsana completed its merger with Cyclerion Therapeutics and raised $380 million through a private placement in September 2026. It ended September with about $456.2 million in cash and equiv | 2026-11-05 |
| Merger with Korsana completed; shareholder approvals obtained at annual meeting Cyclerion Therapeutics merged with Korsana Biopharmaceuticals in a reverse merger transaction that closed on September 9, 2026. Here's what happened: KEY TRANSACTION DETAILS: - Korsana rais | 2026-09-11 |
| Merger agreement with Korsana Biosciences entered into and subsequently amended Cyclerion Therapeutics held a shareholder meeting on August 26, 2026, to vote on a merger with Korsana Biosciences. Shareholders approved the issuance of Cyclerion shares (representing over | 2026-08-27 |
| Company enters merger agreement with Korsana Cyclerion Therapeutics announced on April 1, 2026, that it entered into a merger agreement with Korsana. As part of this transaction, the company updated the employment terms for Regina Grau | 2026-04-01 |
| Licensee initiates Phase 2 clinical trials for licensed drug candidate Cyclerion Therapeutics announced that its partner Akebia Therapeutics has initiated Phase 2 clinical trials for Praliciguat, a drug licensed from Cyclerion, to treat focal segmental glomerul | 2025-12-01 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Korsana Biosciences, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.